Aprezo 30mg Tablet is a clinically established oral pharmaceutical preparation containing Apremilast, a selective phosphodiesterase-4 (PDE4) inhibitor, as its primary active ingredient. It falls under the Dermatology therapeutic class and is widely prescribed for the management of chronic inflammatory skin and joint conditions. Apremilast works by modulating intracellular inflammatory signalling pathways, helping to reduce the skin lesions, scaling and joint inflammation associated with psoriasis and psoriatic arthritis. Manufactured by Glenmark Pharmaceuticals Ltd, Aprezo 30mg Tablet is available in Tablet form and is administered orally, typically as part of a gradual dose-titration schedule. This medicine is classified under the Skin Care general category and the Dermatology speciality domain, reflecting its targeted use in managing chronic dermatological and associated joint conditions. Patients should note that dosage and treatment duration must be individualised based on the patient's clinical condition and response to therapy.

• Chronic Plaque Psoriasis: Indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. • Psoriatic Arthritis: Used for the management of active psoriatic arthritis, helping to reduce joint pain, swelling and stiffness. • Oral Ulcers of Behçet's Disease: May be prescribed for the management of oral ulcers associated with Behçet's disease under specialist guidance. • Combination Therapy: May be used alongside other topical or systemic treatments as advised by a dermatologist or rheumatologist. • Maintenance Therapy: Used for long-term control of chronic plaque psoriasis and psoriatic arthritis symptoms following initial dose titration.

Apremilast, the active ingredient in Aprezo 30mg Tablet, works by selectively inhibiting phosphodiesterase-4 (PDE4), an enzyme that regulates intracellular levels of cyclic AMP (cAMP) within immune cells. By inhibiting PDE4, Apremilast increases cAMP levels, which in turn modulates the production of pro-inflammatory and anti-inflammatory mediators such as TNF-alpha, IL-23 and IL-10. This helps reduce the inflammatory cascade responsible for the skin lesions of psoriasis and the joint inflammation of psoriatic arthritis. The oral bioavailability of Apremilast allows for systemic anti-inflammatory action, with clinical improvement in skin and joint symptoms typically observed over several weeks of consistent use. Therapeutically, Aprezo 30mg Tablet is classified under the Skin Care category and Dermatology speciality domain, and regular clinical monitoring is recommended to evaluate treatment response.

• Strong CYP3A4/CYP450 Enzyme Inducers: Medicines such as rifampicin, phenobarbital, carbamazepine, phenytoin and St. John's Wort may significantly reduce blood levels of Apremilast, reducing its effectiveness — concurrent use is generally not recommended. • Live Vaccines: Inform your doctor before receiving any vaccinations during treatment. • Other Immunomodulatory Agents: Concurrent use with other systemic immunosuppressants should be supervised by a specialist. • Always inform your doctor about every medicine you are currently taking before starting Aprezo 30mg Tablet, including prescription drugs, OTC medications, vitamins and herbal supplements.

For complete prescribing information, refer to the product insert. Consult a dermatologist or rheumatologist before use, particularly regarding the dose-titration schedule recommended for the first two weeks of therapy.